期刊文献+

Castleman病合并贫血的临床分析 被引量:6

Clinical Analysis of Anemia in Castleman Disease
下载PDF
导出
摘要 目的:本研究旨在探讨Castleman病(CD)合并贫血的特征。方法:回顾性研究33例CD患者的临床资料,分析贫血发生率和临床特征,探讨贫血类型及其治疗和疗效。结果:13/33(39%)例CD初诊时有贫血表现,多为轻度,正细胞正色素型。多中心CD(multicentric CD,MCD)贫血发生率高于单中心CD(unicentric CD,UCD)(85%vs 10%)(P<0.001)。与无贫血者相比,CD合并贫血者多具有系统性表现,且血沉、炎症指标(C反应蛋白和纤维蛋白原)水平、多克隆免疫球蛋白增多及自身抗体阳性的发生率均升高(P均<0.05)。进一步分析贫血类型发现,除2例自身免疫性溶血性贫血(AIHA)和1例脾亢继发贫血外,余10例均具有慢性病贫血(ACD)的特征,其血红蛋白水平与C反应蛋白(CRP)及纤维蛋白原均呈负相关(r分别为-0.917、-0.717,P均<0.001)。UCD合并贫血者经肿瘤切除后治愈,MCD合并贫血者经免疫和/或化疗治疗后贫血好转。结论:贫血为MCD常见的系统性表现,亦可见于UCD。除少数表现为AIHA外,多数具有ACD特征。CD合并贫血的治疗以治疗原发病为主。 Objective: This study was to explore the characteristics of anemia in Castleman disease (CD). Methods: Clinical data were collected retrospectively to analyze the prevalence and characteristics of CD with anemia were analysed retrospectively, and different types of anemia and their therapeutic effects were evaluated. Results: Anemia was observed in 13/33 (39%) newly diagnosed CD patients, most of them was mild and normocytic. Incidence of anemia in multicentric CD (MCD) was higher than that in unicentric CD (UCD) ( 85 % vs 10% , P 〈 0.001 ). Most of CD patients with anemia presented systematic manifestations; moreover, they had higher levels of erythrocyte sedimentation and inflammatory indices, higher incidence of polyclonal hyperimmunoglobulinemia, and higher positive rate of autoantibodies than those without anemia ( P 〈 0.05 ). Except for 2 cases of autoimmune hemolytic anemia (AIHA) and 1 case of anemia secondary to hypersplenism, the anemia in the other 10 patients exhibited features similar to anemia of chronic disease (ACD), whose hemoglobin levels were negatively correlated with the serum levels of C reactive protein and fibrinogen (r -0. 917 and -0. 717, respectively,P 〈0.001 ). Anemia in UCD was cured by the removal of tumor. Yet, anemia in MCD was improved after systemic treatment with immunotherapy and/or chemotherapy. Conclusions: anemia with an inflammatory and immunologic mechanism presents as a common symptom in MCD, but also can be observed in UCD. In addition to occasional AIHA, anemia associated with CD mainly presents characteristics of ACD. Treatment for anemia in CD is mainly based on the control of primary disease.
出处 《中国实验血液学杂志》 CAS CSCD 北大核心 2015年第3期696-701,共6页 Journal of Experimental Hematology
关键词 CASTLEMAN病 多中心Castleman病 单中心Castleman病 贫血 Castleman disease multicentric castleman disease unicentric castleman disease anemia
  • 相关文献

参考文献19

  • 1Frizzera G.Castleman's disease and related disorders.Semin Diagn Pathol,1988;5(4):346-364.
  • 2Muzes G,Sipos F,Csomor J,et al.Multicentric Castleman's disease:a challenging diagnosis.Pathol Oncol Res,2013;19(3):345-351.
  • 3Kawabata H,Kadowaki N,Nishikori M,et al.Clinical features and treatment of multicentric castleman's disease:a retrospective study of21 Japanese patients at a single institute.J Clin Exp Hematop,2013;53(1):69-77.
  • 4Shin DY,Jeon YK,Hong YS,et al.Clinical dissection of multicentric Castleman disease.Leuk Lymphoma,2011;52(8):1517-1522.
  • 5Ye B,Gao SG,Li W,et al.A retrospective study of unicentric and multicentric Castleman's disease:a report of 52 patients.Med Oncol,2010;27(4):1171-1178.
  • 6Geary CG,Fox H.Giant lymph node hyperplasia of the mediastinum and refractory anaemia.J Clin Pathol,1978;31(8):757-760.
  • 7Liberato NL,Bollati P,Chiofalo F,et al.Autoimmune hemolytic anemia in multicentric Castleman's disease.Haematologica,1996;81(1):40-43.
  • 8Chandrakasan S,Bakeer N,Mo JQ,et al.Iron-refractory microcytic anemia as the presenting feature of unicentric Castleman disease in children.J Pediatr,2014;164(4):928-930.
  • 9Vinzio S,Ciarloni L,Schlienger JL,et al.Isolated microcytic anemia disclosing a unicentric Castleman disease:The interleukin-6/hepcidin pathway?Eur J Intern Med,2008;19(5):367-369.
  • 10Weiss G,Goodnough LT.Anemia of chronic disease.N Engl J Med,2005;352(10):1011-1023.

同被引文献37

  • 1谢秀萍.缺铁性贫血铁剂治疗前后的血液学指标变化[J].海南医学,2005,16(7):158-159. 被引量:2
  • 2朱学骏,王京,陈喜雪,王仁贵,张澜波,李挺,王爱平,杨淑霞,涂平,李若瑜,吴艳,杨海珍,季素珍.伴发副肿瘤性天疱疮的Castleman瘤——附10例报告[J].中华皮肤科杂志,2005,38(12):745-747. 被引量:37
  • 3Nadia Talat,Ajay P. Belgaumkar,Klaus-Martin Schulte.Surgery in Castleman?s Disease: A Systematic Review of 404 Published Cases[J]. Annals of Surgery . 2012 (4)
  • 4Bo Ye,Shu-Geng Gao,Wang Li,Long-Hai Yang,Shou-Hua Zhao,Ke Ma,Xiao-Lei Zhu,Xiang-Yang Liu,Ke-Ling Sun.A retrospective study of unicentric and multicentric Castleman’s disease: a report of 52 patients. Medical Oncology . 2010
  • 5Talat Nadia,Schulte Klaus-Martin.Castleman’s Disease: Systematic Analysis of 416 Patients from the Literature. The Oncologist . 2011
  • 6CastlemanB, IversonL, MenendezVP. Localizedme diastinallymp hnodehype rplasiaresemblingthymoma [ J ]. Cancer, 19 5 6, 9 ( 4 ) :822-30.
  • 7Muskardin TW, Pheumatol BA, Molitor JA. Castleman disease and as- sociated autoimmune disease[J ]. Curr Opin Rheumatol, 2012, 24(1):76 - 83.
  • 8Shah D, Darji P, Lodha S, et al. UnieentricCastleman'sdisease o- fabdomen [ J ]. JRadiolCaseRep, 2013, 7 ( 3 ) : 26 - 33.
  • 9Deisseroth A, Ko CW, Nie L, et d. FDA approval: sihuximb for the treatment of patients with muhicenlric castteman disease[J ]. Clin Cancer Res, 2015, 21(5) :950 - 954.
  • 10刘宁,邱法波,李奉达.Castleman's病流行病学及临床特征[J].世界华人消化杂志,2008,16(30):3469-3473. 被引量:44

引证文献6

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部